Rituximab improves outcomes in low-risk diffuse large B-cell lymphoma

NEW YORK (Reuters Health) - Progression-free survival in younger patients with low-risk localized diffuse large B-cell lymphoma (DLBCL) is better when rituximab is added to a chemotherapy regimen currently considered optimal, a European team reports.
Source: Modern Medicine - Category: Journals (General) Source Type: news